Peripheral blood eosinophilia has been reported to occur in a wide range of haematological malignancies including primary cutaneous lymphomas. The concurrence of lymphomatoid papulosis (LyP) with peripheral blood eosinophilia seems to be an uncommon phenomenon. Atypical lymphocytes in LyP display the phenotype of activated T-helper cells, consistently express CD30 antigen, have a Th2 cytokine profile, and secrete eosinophil-stimulating cytokines. Cases of LyP have been reported in association with myeloproliferative hypereosinophilic syndrome (M-HES) presenting the Fip1-like 1/platelet-derived growth factor receptor-α (FIP1L1-PDGFRα) fusion gene. In such cases, imatinib treatment may lead to a complete and persistent resolution of LyP lesions.

CASE REPORT

A 25-year-old man was referred to our Department in November 2011 for evaluation of a 3-year history of recurrent crops of self-healing erythematous papules and nodules with central ulceration on the lower extremities, oral mucosa and face. Biopsy had established the diagnosis of LyP. The patient reported periodical appearance of lesions that regressed spontaneously leaving residual scars. His past medical history revealed childhood-onset asthma, allergic conjunctivitis and rhinitis. Peripheral eosinophilia of 1,200/mm³ had also been detected and was related to the allergic symptoms along with progressive cough and discrete dyspnoea.

Physical examination disclosed a firm, well-demarcated, painless, ulcerated nodule, 1.2 cm in diameter on the right aspect of the chin. Several erythematous papules and residual scars on the lower extremities were also observed. A solitary nodule with a central ulcer was noted on the left leg (Fig. 1a, b). No enlarged lymph nodes were detected.

Two 4-mm punch biopsies from different lesions disclosed a dense, dermal, wedge-shaped infiltrate with clusters of large atypical lymphoid cells admixed with small lymphocytes, histiocytes, neutrophils and eosinophils. Neoplastic cells were CD30¹ and expressed mature T helper cell markers (CD3, CD2, CD5 and CD7, CD4). No expression of ALK, c-KIT or CD56 was detected. Neoplastic cells were also MUM-1¹ and 60% of cells expressed Ki-67 antigen. In both biopsy specimens, an identical clonal rearrangement of the T-cell receptor (TCR) γ and β chains was detected. No T-cell clonality was detected in peripheral blood samples.

Laboratory tests disclosed massive peripheral eosinophilia (6,120/mm³), normal IgE levels, elevated tryptase (15.5 ng/ml) (NV < 13.5) and vitamin B12 serum levels (>2,000 ng/ml) (NVs: 197–866). Stools for ova and parasites were negative. Body computed tomography (CT) showed bronchial dilatation with peribronchial thickening and confluent centrolobulillar nodules forming a ground glass pattern. Electrocardiogram, echocardiogram and ophthalmological examination showed no abnormalities.

A bone marrow biopsy was obtained showing hypercellular marked eosinophilia, atypical spindle-shaped mast cells and increased reticulin fibrosis. Interstitial deletion of the 4q12 ch...
18 chromosome band comprising LNX, CHIC2 and PDGFRA genes leading to a FIP1L1-PDGFRα rearrangement was detected by fluorescence in situ hybridization (FISH) in peripheral blood cells (Fig. 1g). The deletion was present in eosinophils (46%), mast cells (100%) and granulocytes (45%) analysed from peripheral blood isolated populations. This led to the diagnosis of hypereosinophilic syndrome secondary to FIP1L1-PDGFRα myeloid neoplasm. The presence of FIP1L1-PDGFRα fusion gene was analysed by FISH in skin biopsy specimens of LyP. No individual cells were found to bear the translocation (Fig. 1b).

Treatment with imatinib mesilate (100 mg/day) was prescribed in February 2012. Regression of the cutaneous lesions and a rapid normalization of the eosinophil count were observed. After 8 months of treatment, a sustained response of both hematological and eosinophilic parameters were maintained (Fig. 1h).

DISCUSSION

Characteristically, LyP is manifested by recurrent development of papulo-nodular lesions that undergo spontaneous regression after weeks or months. Many different therapeutic options have been proposed; nevertheless, after treatment discontinuation, relapses tend to occur (1) and no therapy has proven to alter the course of the disease nor prevent LyP-associated lymphomas.

Since the original description, 11 cases of LyP associated with idiopathic HES have been reported (2–9). The associated HES corresponded to M-HES and specifically to patients presenting the FIP1L1-PDGFRα fusion gene, the most well-characterized molecular defect leading to hypereosinophilia (10). This subset of HES is characterized by splenomegaly, elevated serum B12 and trypsin levels, myeloproliferation and tissue fibrosis. Patients usually show a dramatic response to imatinib, which targets these genes (11).

The mechanisms implicated in the concurrent development of M-HES and LyP remain obscure. Clonal T cells bearing the FIP1L1-PDGFRα rearrangement have been identified in some patients with PDGFRα-associated HES, moreover, cases associating M-HES and T-cell lymphoblastic lymphoma in which both disorders carried the same FIP1L1-PDGFRα rearrangement have been reported (12, 13). Conversely, a non-LyP CD30+ clonal T-cell proliferation associated with non-FIP1L1-PDGFRα HES has been described recently, supporting the role of HES in the development of a clonal T-cell proliferations (14). A multilineage clonal population has also been postulated as the most likely explanation for the M-HES-LyP association (15). However, in our case we have been unable to demonstrate the presence of the specific translocation in cutaneous infiltrates of LyP lesions. The possibility that the neoplastic population bearing the FIP1L1-PDGFRα fusion gene could be beyond the threshold of FISH detection, although improbable, cannot be disregarded. Therefore, the possibility that independent genetic events may engender this association cannot be excluded.

Since 2003, imatinib was prescribed in 7 cases of M-HES associated with LyP (Table S1). In 4 of these, the FIP1L1-PDGFRα fusion gene was demonstrated. A rapid regression of the cutaneous lesions was noted and a persistent, complete clinical, haematological and molecular remission was achieved (4, 6). No recurrences of LyP have been observed after variable follow-up periods. In our case, no new lesions have developed after a 5-year follow-up period.

The mechanisms implied in this constant response have not been elucidated. This parallel effect in both LyP and M-HES has not been observed in cases previously treated with regimes not including imatinib (2, 3). These observations could suggest that tyrosine kinase-mediated mechanisms play a role in the development of LyP. Furthermore, the possibility that this therapeutic effect could be a phenomena not restricted to the subset of LyP patients associated with M-HES has not been evaluated.

The authors declare no conflicts of interest.

REFERENCES


https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-2016

www.medicaljournals.se/acta


Dear Author,

Some questions have arisen during the preparation of your manuscript for typesetting. These are marked in the text by [AQ#]. Please consider the points below and make any corrections required.

**AQ1:** Magnification in parts (g) and (h)?

**AQ2:** This is just an Abstract. If not published, the reference should be removed and data given in a footnote.

**AQ3:** Please also give ref numbers, to match those in the ref list.

Many thanks
Supplementary material to article by P. García-Martínez et al. “Imatinib Treatment of Lymphomatoid Papulosis Associated with Myeloproliferative Hypereosinophilic Syndrome Presenting the FIP1L1-PDGFA Fusion Gene”

Table SI. Cases of hypereosinophilic syndrome (HES) associated with lymphomatoid papulosis (LyP) treated with imatinib mesilate

<table>
<thead>
<tr>
<th>Author (year)</th>
<th>Age/Sex</th>
<th>LyP onset</th>
<th>LyP appearance and location</th>
<th>Eosinophil count/mm³</th>
<th>Diagnosis</th>
<th>FIP1L1-PDGFA fusion gene</th>
<th>Systemic involvement</th>
<th>Treatment dosage</th>
<th>Response Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koury et al. (2003)</td>
<td>51/M</td>
<td>P (1 y)</td>
<td>ND</td>
<td>2,000–8,000/mm³</td>
<td>Idiopathic HES</td>
<td>ND</td>
<td>Lung, heart</td>
<td>Mepolizumab + Imatinib mesilate 400 mg/d × 2 w. 200 mg/d × 7 m. 100 mg/d × 11 m.</td>
<td>CR (C,H) 18 m.</td>
</tr>
<tr>
<td>McPherson et al. (2006)</td>
<td>33/M</td>
<td>P (5 m)</td>
<td>Ulcerated papules Thighs and torso</td>
<td>5,170/mm³</td>
<td>Idiopathic HES</td>
<td>BM: Present</td>
<td>Bone marrow</td>
<td>Imatinib mesilate 100 mg/d</td>
<td>CR (C,H) 9 m.</td>
</tr>
<tr>
<td>Fujimi et al. (2007)</td>
<td>68/M</td>
<td>P (1 y)</td>
<td>Ulcerated papules Neck, arm, trunk</td>
<td>8,700/mm³</td>
<td>Idiopathic HES</td>
<td>BM: Present</td>
<td>Lung, splenomegaly</td>
<td>Imatinib mesilate 400 mg/d</td>
<td>CR (H) 12 m.</td>
</tr>
<tr>
<td>Klon et al. (2010)</td>
<td>34/M</td>
<td>ND</td>
<td>ND</td>
<td>395/mm³</td>
<td>CEL</td>
<td>BM: Present</td>
<td>ND</td>
<td>Imatinib mesilate 100 mg/d</td>
<td>CR (H) ND</td>
</tr>
<tr>
<td>Currelli et al. (2010)</td>
<td>32/M</td>
<td>P (2 y)</td>
<td>Papules Lower legs</td>
<td>19,500/mm³</td>
<td>Idiopathic HES</td>
<td>ND</td>
<td>Lung, heart, liver</td>
<td>Imatinib mesilate 100 mg/d</td>
<td>CR (C,H) ND</td>
</tr>
<tr>
<td>Thuny et al. (2010)</td>
<td>51/M</td>
<td>S</td>
<td>Papules Neck, limbs</td>
<td>3,500/mm³</td>
<td>CEL</td>
<td>BM: Present</td>
<td>ND</td>
<td>Imatinib mesilate 100 mg/d</td>
<td>CR (C,H) ND</td>
</tr>
<tr>
<td>Present case</td>
<td>25/M</td>
<td>S</td>
<td>Ulcerated papules Trunk, extremities, oral mucosa</td>
<td>1,200–7,900/mm³</td>
<td>M-HES</td>
<td>BM: Present</td>
<td>Skin: Not present</td>
<td>Imatinib mesilate 100 mg/d × 8 m. 500 mg/w × 3 m. 300 mg/w × 9 m. 200 mg/w × 12 m. 100 mg/week to date</td>
<td>CR (C,H) 58 m.</td>
</tr>
</tbody>
</table>

Diagnosis given by authors when reported.
P: preceding, S: simultaneously, y: years; m: months; w: weeks; d: days; F: following the diagnosis of HES, ND: no data; HES: hypereosinophilic syndrome; CEL: chronic eosinophilic leukaemia; BM: bone marrow CR: complete remission; C: cutaneous; H: haematological; M-HES: myeloproliferative hypereosinophilic syndrome.

Fig. S1. Effect of imatinib mesilate (dosage per week) on blood eosinophil count and over the activity of lymphomatoid papulosis (LyP) (expressed as new cutaneous lesions per month).